{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'Durability in TSQM scores', 'Durability in WPAI scores', '7.1.8.', 'Part 3 Primary Enppoints', 'Number and proportion of subjects with a TEAE', 'Number and proportion of subjects who discontinue due to a TEAE', 'Number and proportion of subjects who experience a TESAE', 'Number and proportion of subjects who experience a Grade 3 or 4 TEAE', 'Number and proportion of subjects who experience a treatment-emergent Grade 3 or', '4 laboratory abnormality', 'The proportion of subjects with a treatment-emergent, treatment related AE consistent', 'with a drug rash', '7.1.9.', 'Part 3 Secondary Enppoints', 'Number and rate of HAE attacks', 'Durability of response (attack rate trend over time)', 'Number and proportion of days with angioedema symptoms', 'Use of HAE attack medications', 'Durability in AE-QoL questionnaire scores', 'Durability in EQ-5D-5L scores', 'Durability in TSQM scores', 'Durability in WPAI scores', '8.', 'SELECTION AND WITHDRAWAL OF SUBJECTS', '8.1.', 'Number of Subjects', 'Approximately 96 subjects are planned to be enrolled in the study, which includes any', 'adolescent patients enrolled in the substudy; additional subjects may be required after the', 'potential sample size re-estimation based on the pooled, blinded SD of the weekly attack rate', 'following 50% of subjects completing 24 weeks.', '8.2.', 'Subject Selection', '8.2.1.', 'Inclusion Criteria', 'Subjects must meet all of the following inclusion criteria to be eligible for participation in this', 'study:', '39']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '1. Males and non-pregnant, non-lactating females > 18 years of age (main study) or > 12 to', '17 years of age (substudy).', '2. Able to provide written, informed consent. Subjects who are aged 12 to 17 years of age at', 'screening for the substudy must be able to read, understand, and be willing to sign an', 'assent form in addition to a caregiver providing informed consent.', '3. Subject weight of > 40 kg.', '4. A clinical diagnosis of HAE Type I or Type II, defined as having a C1-INH functional', 'level below 50% and a complement 4 (C4) level below the lower limit of the normal', '(LLN) reference range, as assessed during the Screening period.', 'In the absence of a low C4 value drawn during the intercritical period (ie, subject is not', 'having an HAE attack), 1 of the following is acceptable to confirm the diagnosis of HAE:', '1) a SERPING-1 gene mutation known or likely to be associated with HAE Type I or II', 'assessed during the screening period; 2) a confirmed family history of C1-INH', 'deficiency; 3) a C4 redrawn and retested during an attack in the screening period with the', 'results below the LLN reference range.', 'For subjects with C1-INH function > 50% but less than the assay LLN, a SERPING-1', 'gene mutation known or likely to be associated with HAE Type I or II, as assessed during', 'the screening period OR a repeat C1-INH functional level < 50% will be considered', 'acceptable for enrollment.', 'If a subject has a normal C4 at the screening visit and it is desired to utilize a family', 'history of C1-INH deficiency to establish an HAE diagnosis for eligibility, the', \"Investigator should document this as a source file note based on either the Investigator's\", 'personal knowledge (ie, if a relative of the screening subject is also a patient of the same', 'Investigator/practice) or interaction with medical staff of the treatment facility where the', 'relative receives HAE care, who confirms the diagnosis. No historical laboratory', 'documentation on the relative should be collected in the source documents.', 'If a subject has a normal C4 at the screening visit and has C4 subsequently retested', 'during an attack, C4 must be less than the LLN to establish an HAE diagnosis for', 'eligibility. Normal C4 drawn during an attack excludes the subject from study', 'participation.', 'For patients with a normal C4 at the screening visit, historical SERPING analysis will not', 'be permitted to establish eligibility. Mutations known to be associated with HAE or those', 'that are likely associated with HAE (ie an unidentified mutation in the active binding site', 'of C1-INH) will be accepted.', '5. Access to and ability to use one or more acute medications approved by the relevant', 'competent authority for the treatment of acute attacks of HAE (icatibant, plasma-derived', 'C1-INH, ecallantide, or recombinant C1-INH). Cinryze used for acute treatment of HAE', 'attacks is an acceptable medication for this purpose.', '6. Subjects must be medically appropriate for on-demand treatment as the sole medicinal', 'management for their HAE during the study.', '40']\n\n###\n\n", "completion": "END"}